Nicholas P. Diorio

FDA investigator

Appears on 8 documents from 2013 to 2025, mostly at sites in Illinois. Most often cites testing and release for distribution (21 CFR 211.165(a)).

8
Documents on file
5.8
Observations per 483
2013
First seen
2025
Most recent

What they cite most

From 46 observations

Activity by year

2013: 1, 2015: 1, 2016: 1, 2017: 1, 2018: 1, 2019: 1, 2022: 1, 2025: 1

Where

Illinois 7 · Florida 1

Is Nicholas P. Diorio coming to your site?

Our team writes custom reports before an inspection: what this investigator cites most, how they write it up, and how your site's history compares, in one brief you can circulate.

Ask about any investigator in Claude or ChatGPT with the AI connector.

Inspection history

8 documents, newest first
FirmOpen
483 Korex Chicago LLCFeb 7, 2025 · Chicago, Illinois
483 American Chinese Medicine AssociationJan 20, 2022 · Aurora, Illinois
483 Novum Pharma, LLCSep 24, 2019 · Chicago, Illinois
483 Xttrium Laboratories, Inc.Mar 15, 2018 · Mount Prospect, Illinois
483 Primrose Candy CompanySep 26, 2017 · Chicago, Illinois
483 Sage Products Inc 'Sep 1, 2016 · Cary, Illinois
483 AbbVie IncAug 6, 2015 · North Chicago, Illinois

About this profile

What does Nicholas P. Diorio inspect?

Nicholas P. Diorio appears on 8 documents on file covering 8 sites, mostly in Illinois.

What do they cite most often?

21 CFR 211.165(a) (testing and release for distribution), followed by 21 CFR 211.113(a) and 21 CFR 211.166(a).

Can I read the observations?

Each document page previews the opening words of every observation. The full documents are available to buy, one at a time or together.

How current is this profile?

The most recent document on file for Nicholas P. Diorio is dated Feb 7, 2025.